Q3 EPS Estimates for Zimmer Biomet Reduced by Zacks Research

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) – Zacks Research lowered their Q3 2025 earnings per share estimates for shares of Zimmer Biomet in a research report issued on Monday, November 25th. Zacks Research analyst R. Department now forecasts that the medical equipment provider will earn $1.95 per share for the quarter, down from their prior estimate of $1.98. The consensus estimate for Zimmer Biomet’s current full-year earnings is $7.99 per share. Zacks Research also issued estimates for Zimmer Biomet’s FY2025 earnings at $8.48 EPS, Q1 2026 earnings at $2.27 EPS, Q2 2026 earnings at $2.34 EPS, Q3 2026 earnings at $2.20 EPS and FY2026 earnings at $9.13 EPS.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings results on Wednesday, October 30th. The medical equipment provider reported $1.74 EPS for the quarter, hitting analysts’ consensus estimates of $1.74. The business had revenue of $1.82 billion for the quarter, compared to analyst estimates of $1.80 billion. Zimmer Biomet had a return on equity of 12.95% and a net margin of 14.27%. Zimmer Biomet’s revenue for the quarter was up 4.1% on a year-over-year basis. During the same period in the prior year, the company earned $1.65 EPS.

ZBH has been the topic of a number of other reports. Robert W. Baird decreased their price target on Zimmer Biomet from $155.00 to $145.00 and set an “outperform” rating on the stock in a research report on Thursday, August 8th. Raymond James decreased their price objective on Zimmer Biomet from $128.00 to $123.00 and set an “outperform” rating on the stock in a research report on Monday, October 14th. Wolfe Research assumed coverage on Zimmer Biomet in a research report on Tuesday, September 10th. They issued a “peer perform” rating on the stock. Needham & Company LLC reiterated a “hold” rating on shares of Zimmer Biomet in a research report on Thursday, October 31st. Finally, Canaccord Genuity Group decreased their price objective on Zimmer Biomet from $120.00 to $115.00 and set a “hold” rating on the stock in a research report on Tuesday, September 10th. Two investment analysts have rated the stock with a sell rating, twelve have assigned a hold rating and seven have issued a buy rating to the company. According to MarketBeat, Zimmer Biomet presently has an average rating of “Hold” and a consensus target price of $123.22.

Zimmer Biomet Stock Up 1.3 %

NYSE ZBH opened at $112.06 on Wednesday. The firm has a market cap of $22.31 billion, a PE ratio of 21.30, a price-to-earnings-growth ratio of 2.04 and a beta of 1.02. Zimmer Biomet has a one year low of $101.47 and a one year high of $133.90. The stock’s 50 day simple moving average is $107.07 and its 200 day simple moving average is $109.49. The company has a debt-to-equity ratio of 0.38, a current ratio of 1.36 and a quick ratio of 0.70.

Institutional Trading of Zimmer Biomet

Several hedge funds have recently added to or reduced their stakes in ZBH. Dunhill Financial LLC raised its stake in Zimmer Biomet by 1,090.0% during the 3rd quarter. Dunhill Financial LLC now owns 238 shares of the medical equipment provider’s stock worth $26,000 after buying an additional 218 shares during the period. Ashton Thomas Securities LLC acquired a new stake in Zimmer Biomet during the 3rd quarter worth $28,000. Bangor Savings Bank acquired a new stake in Zimmer Biomet during the 3rd quarter worth $31,000. Family Firm Inc. acquired a new stake in Zimmer Biomet during the 2nd quarter worth $33,000. Finally, Brooklyn Investment Group acquired a new stake in Zimmer Biomet during the 3rd quarter worth $35,000. Institutional investors and hedge funds own 88.89% of the company’s stock.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.